Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
- - -
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | CN¥113.48B |
EV | CN¥112.33B |
Shares Outstanding | 401.00M |
Beta | 1.24 |
Analyst Rating | BUY |
Analyst Target Price | CN¥307.04 |
P/E 2025E | - |
P/Revenue 2025E | 50.59x |
Revenue | 94.10% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | -45.60% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 74.26% |
Net Profit Margin 2025E | 2.78% |
ROE 2025E | 1.54% |
ROCE 2024 | 183.64% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Sichuan Biokin Pharmaceutical Co.,Ltd.
688506
Sector
Industry
CEO
Zhu, Yi
Employees
2,086
Website
www.baili-pharm.comIPO Date
Headquarters
No.1, Building 1, No. 161 Baili Road, Cross-Strait Science and Technology Park, Wenjiang District, Chengdu, Sichuan Province, 611130, China
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved